Mortality and morbidity in transsexual subjects treated with cross‐sex hormones
- P. V. van Kesteren, H. Asscheman, J. Megens, L. Gooren
- Medicine, PsychologyClinical Endocrinology
- 1 September 1997
Investigation of mortality and morbidity figures in a large group of transsexual subjects receiving cross‐sex hormone treatment finds that the optimum steroid hormone treatment regimes for transsexual subjects has not yet been established.
A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
- H. Asscheman, E. Giltay, J. Megens, W. de Ronde, M. V. van Trotsenburg, L. Gooren
- MedicineEuropean Journal of Endocrinology
- 1 April 2011
The increased mortality in hormone-treated MtF transsexuals was mainly due to non-hormone-related causes, but ethinyl estradiol may increase the risk of cardiovascular death, and use of testosterone in doses used for hypogonadal men seemed safe.
Mortality and morbidity in transsexual patients with cross-gender hormone treatment.
- H. Asscheman, L. Gooren, P. Eklund
- MedicineMetabolism: Clinical and Experimental
- 1 September 1989
Direct medical costs of adverse events in Dutch hospitals
- L. Hoonhout, M. D. de Bruijne, M. V. van Tulder
- Medicine, Political ScienceBMC Health Services Research
- 9 February 2009
The estimates of the total preventable direct medical costs of AEs indicate that they form a substantial part of the expenses of the national health care budget and are of importance to hospital management.
Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects
objective Sex differences are found in most components of the insulin resistance syndrome and the associated cardiovascular risk profile. These differences are attributed to sex‐specific sex steroid…
Long‐term follow‐up of bone mineral density and bone metabolism in transsexuals treated with cross‐sex hormones
- P. V. van Kesteren, P. Lips, L. Gooren, H. Asscheman, J. Megens
- Medicine, BiologyClinical Endocrinology
- 1 March 1998
It is unknown whether long term cross‐sex hormone treatment affects the human skeleton, and bone mineral density and biochemical markers of bone turnover in male‐to‐female transsexuals treated with anti‐androgens and oestrogens and those treated with androgens are monitored.
Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals.
- J. Elbers, H. Asscheman, J. Seidell, L. Gooren
- Medicine, BiologyAmerican Journal of Physiology. Endocrinology and…
- 1 February 1999
It is concluded that sex steroid hormones are important determinants of the sex-specific localization of body fat in adult transsexuals.
Induction of insulin resistance by androgens and estrogens.
- K. Polderman, L. Gooren, H. Asscheman, A. Bakker, R. Heine
- Medicine, BiologyJournal of Clinical Endocrinology and Metabolism
- 1 July 1994
It is concluded that sex hormone administration, i.e. testosterone treatment in females and ethinyl estradiol treatment in males, can induce insulin resistance in healthy subjects.
Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals.
- J. Elbers, H. Asscheman, J. Seidell, M. Frölich, A. Meinders, L. Gooren
- Medicine, BiologyJournal of Clinical Endocrinology and Metabolism
- 1 October 1997
The results indicate that sex steroid hormones, in particular testosterone, play an important role in the regulation of serum leptin levels and that the prevailing sex steroid milieu, not genetic sex, is a significant determinant of the sex difference in serumptin levels.
Venous thrombo‐embolism as a complication of cross‐sex hormone treatment of male‐to‐female transsexual subjects: a review
- H. Asscheman, G. T’Sjoen, L. Gooren
- Medicine, BiologyAndrologia
- 1 September 2014
It seems advisable to stop hormone use at least 2 weeks before major surgery, to be resumed only after 3 weeks following full mobilisation, and other oral oestrogens should not be overdosed, and transdermal oestrogen is to be preferred.
...
...